Recent News

• 11.04.2026 - Progyny, Inc. Announces Third Quarter 2026 Results
• 10.28.2026 - New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
• 10.26.2026 - New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
• 10.21.2026 - Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
• 10.15.2026 - Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
• 10.07.2026 - Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
• 09.05.2026 - Menopause hormone therapy: Is it right for me?
• 09.04.2026 - Coping with perimenopause and menopause at work
• 09.04.2026 - Sleep problems in perimenopause and menopause
• 09.04.2026 - Vaginal and urinary symptoms in perimenopause and menopause

Recent Filings

• 11.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2026 - 8-K Current report
• 11.04.2026 - 144 Report of proposed sale of securities
• 11.04.2026 - EX-99.1 EX-99.1
• 10.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.14.2026 - 144 Report of proposed sale of securities
• 09.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.23.2026 - 144 Report of proposed sale of securities
• 09.21.2026 - 4 Statement of changes in beneficial ownership of securities